267 related articles for article (PubMed ID: 25152578)
1. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
2. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.
Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D
Cancer Cell; 2013 Mar; 23(3):406-20. PubMed ID: 23453624
[TBL] [Abstract][Full Text] [Related]
3. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
5. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
6. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
7. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
9. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
[TBL] [Abstract][Full Text] [Related]
10. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
Mallucci L; Shi DY; Davies D; Jordan P; Nicol A; Lotti L; Mariani-Costantini R; Verginelli F; Wells V; Zicha D
Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
[TBL] [Abstract][Full Text] [Related]
11. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
[TBL] [Abstract][Full Text] [Related]
12. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
13. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
15. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
[TBL] [Abstract][Full Text] [Related]
16. The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.
Chen Z; Chen M; Fu Y; Zhang J
Pathol Res Pract; 2023 Aug; 248():154603. PubMed ID: 37356222
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS signalling in pancreatic cancer.
Eser S; Schnieke A; Schneider G; Saur D
Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
[TBL] [Abstract][Full Text] [Related]
18. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
Wang K; Baldwin GS; Nikfarjam M; He H
World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
[TBL] [Abstract][Full Text] [Related]
19. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
20. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
